CSIMarket
 


Cellectis S a   (CLLS)
Other Ticker:  
 
 

CLLS's Net Cash Flow Growth by Quarter and Year

Cellectis S A 's Net Cash Flow results by quarter and year




CLLS Net Cash Flow (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.00 241.15 340.52 451.50
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   0.00 241.15 340.52 451.50



CLLS Net Cash Flow fourth quarter 2022 Y/Y Growth Comment
Cellectis S a in the fourth quarter 2022 recorded net cash outflow of $ 0.00 millions.

According to the results reported in the fourth quarter 2022, Cellectis S A achieved the best Net Cash Flow growth in Biotechnology & Pharmaceuticals industry. While Cellectis S A ' s Net Cash Flow no change of % ranks overall at the positon no. in the fourth quarter 2022.




CLLS Net Cash Flow ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -29.18 % -24.58 % 76.11 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - -29.18 % -24.58 % 76.11 %

Financial Statements
Cellectis S A 's fourth quarter 2022 Net Cash Flow $ 0.00 millions CLLS's Income Statement
Cellectis S A 's fourth quarter 2021 Net Cash Flow $ 241.15 millions Quarterly CLLS's Income Statement
New: More CLLS's historic Net Cash Flow Growth >>


CLLS Net Cash Flow (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - -29.18 % -24.58 % 76.11 %




Net Cash Flow fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Cellectis S A 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CLLS's IV. Quarter Q/Q Net Cash Flow Comment


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CLLS's IV. Quarter Q/Q Net Cash Flow Comment


Cellectis S A 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
0
12 Months Ending
(Dec 31 2020)
Cumulative Net Cash Flow 12 Months Ending $ 0.00 $ 0.00 $ 241.15 $ 0.00 $ 340.52
Y / Y Net Cash Flow Growth (TTM) - - -29.18 % - -24.58 %
Year on Year Net Cash Flow Growth Overall Ranking # 255 # 0 # 0 # 0 # 282
Seqeuential Net Cash Flow Change (TTM) - - - - -
Seq. Net Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Net Cash Flow growth Comment
In the Dec 31 2022 period, Cellectis S A 's cumulative trailing twelve month Net Cash Flow remained unchanged compare to the same period a year ago.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 0 to 255.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector # 49
Overall # 255

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
76.11 %
7.45 %
-29.18 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Cash Flow growth Comment
In the Dec 31 2022 period, Cellectis S A 's cumulative trailing twelve month Net Cash Flow remained unchanged compare to the same period a year ago.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Net Cash Flow growth total ranking has deteriorated compare to previous quarter from 0 to 255.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector # 49
Overall # 255

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
76.11 %
7.45 %
-29.18 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
CLLS's Net Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for CLLS's Competitors
Net Cash Flow Growth for Cellectis S A 's Suppliers
Net Cash Flow Growth for CLLS's Customers

You may also want to know
CLLS's Annual Growth Rates CLLS's Profitability Ratios CLLS's Asset Turnover Ratio CLLS's Dividend Growth
CLLS's Roe CLLS's Valuation Ratios CLLS's Financial Strength Ratios CLLS's Dividend Payout Ratio
CLLS's Roa CLLS's Inventory Turnover Ratio CLLS's Growth Rates CLLS's Dividend Comparisons



Companies with similar Net Cash Flow no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2022
Brainsway Ltd -0.24%$ -0.236 millions
Astrazeneca Plc-2.58%$ -2.575 millions
Nuvasive Inc-3.04%$ -3.040 millions
Purple Biotech Ltd -3.17%$ -3.174 millions
Mannkind Corporation-3.54%$ -3.545 millions
Calliditas Therapeutics Ab-4.09%$ -4.095 millions
Pharming Group N v -6.45%$ -6.451 millions
China Health Industries Holdings Inc -6.68%$ -6.684 millions
Galectin Therapeutics Inc -9.42%$ -9.416 millions
Cabaletta Bio Inc -10.05%$ -10.045 millions
Silk Road Medical Inc -11.70%$ -11.702 millions
Gsk Plc-12.89%$ -12.892 millions
Valneva Se-16.52%$ -16.515 millions
Inventiva S a -18.10%$ -18.104 millions
Xtl Biopharmaceuticals Ltd -18.23%$ -18.232 millions
Actavia Life Sciences Inc -19.83%$ -19.832 millions
Marpai Inc -20.85%$ -20.848 millions
Biolinerx Ltd -22.82%$ -22.821 millions
Ascendis Pharma A-23.65%$ -23.652 millions
Innate Pharma Sa-24.15%$ -24.151 millions
Apeiron Capital Investment Corp -26.15%$ -26.147 millions
Gilead Sciences Inc -26.95%$ -26.947 millions
4d Molecular Therapeutics Inc -27.91%$ -27.912 millions
American Shared Hospital Services-27.95%$ -27.945 millions
Koninklijke Philips Nv-28.61%$ -28.611 millions
Edap Tms Sa-29.06%$ -29.064 millions
Nanobiotix S a -29.57%$ -29.568 millions
Protagenic Therapeutics Inc new-29.84%$ -29.844 millions
Nucana Plc-31.01%$ -31.013 millions
Nls Pharmaceutics Ltd -34.10%$ -34.104 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com